Bone loss (osteoporosis and bone erosion) is caused by increased osteoclast activity, although the link between TNF-inhibitory therapy and osteoclast activity has been debated; however, most findings indicate that TNF-inhibitory therapy leads to the inhibition of osteoblast differentiation [46–48]. This evidence concerns the gene TNF and osteoporosis.